Carles Galdeano advances small‑molecule modalities spanning medicinal chemistry, chemical biology and computation. He holds 2 issued patents and licensed IP to a US startup, has secured >$800K in funding, and leads programs in targeted protein degradation and E3‑ligase allostery.